Blinatumomab, a bispecific antibody construct targeting CD19, is the most advanced member of bispecific T-cell engager (BiTE(®)) molecules. The clinical development program includes B-precursor acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (NHL). Minimal residual disease (MRD) response in patients with MRD-positive B-precursor ALL has translated into long-term clinical benefits as demonstrated by an estimated relapse-free survival (RFS) of 60% with sustained MRD negativity at a follow-up of 31 months. Remissions induced in pediatric and adult patients with relapsed/refractory B-precursor ALL have allowed for successful allogeneic hematopoietic stem cell transplantation (HSCT) in this setting. Blinatumomab has also i...
Mark R LitzowMayo Clinic, Rochester, MN, USAAbstract: Acute lymphoblastic leukemia (ALL) arises from...
ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab Tho...
Introduction: In ALL, minimal residual disease (MRD) is defined as the detection of leukemic cells i...
The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precurs...
International audiencePatients with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukem...
Blinatumomab is a BiTE® (bispecific T-cell engager) immuno-oncology therapy, which has demonstrated ...
Abstract Blinatumomab, a bispecific T cell engager (BiTE) antibody targeting CD19 and CD3ε, can redi...
AbstractBlinatumomab is a BiTE® (bispecific T‐cell engager) immuno‐oncology therapy, which has demon...
Immunotherapy is the most rapidly evolving field in clinical malignant hematology. Targeting of the ...
The bispecific T cell engager blinatumomab has shown encouraging clinical activity in B-precursor ac...
Chronic lymphocytic leukemia is an incurable B-cell malignancy that is associated with tumor cell-me...
[[abstract]]Blinatumomab, a bispecific T cell engager (BiTE) antibody targeting CD19 and CD3ε, can r...
Background: Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unf...
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous i...
Immunotherapy is the revolution in cancer treatment of this last decade. Among multiple approaches a...
Mark R LitzowMayo Clinic, Rochester, MN, USAAbstract: Acute lymphoblastic leukemia (ALL) arises from...
ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab Tho...
Introduction: In ALL, minimal residual disease (MRD) is defined as the detection of leukemic cells i...
The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precurs...
International audiencePatients with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukem...
Blinatumomab is a BiTE® (bispecific T-cell engager) immuno-oncology therapy, which has demonstrated ...
Abstract Blinatumomab, a bispecific T cell engager (BiTE) antibody targeting CD19 and CD3ε, can redi...
AbstractBlinatumomab is a BiTE® (bispecific T‐cell engager) immuno‐oncology therapy, which has demon...
Immunotherapy is the most rapidly evolving field in clinical malignant hematology. Targeting of the ...
The bispecific T cell engager blinatumomab has shown encouraging clinical activity in B-precursor ac...
Chronic lymphocytic leukemia is an incurable B-cell malignancy that is associated with tumor cell-me...
[[abstract]]Blinatumomab, a bispecific T cell engager (BiTE) antibody targeting CD19 and CD3ε, can r...
Background: Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unf...
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous i...
Immunotherapy is the revolution in cancer treatment of this last decade. Among multiple approaches a...
Mark R LitzowMayo Clinic, Rochester, MN, USAAbstract: Acute lymphoblastic leukemia (ALL) arises from...
ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab Tho...
Introduction: In ALL, minimal residual disease (MRD) is defined as the detection of leukemic cells i...